Positioning Other Systemic Options and Managing Therapy After PRRT in Progressive Pancreatic Neuroendocrine Tumor

This section explores where commonly used systemic therapies fit within the treatment continuum and how prior PRRT exposure influences subsequent decisions. Dr Shaheen discusses everolimus, sunitinib, and temozolomide based regimens as established options that remain relevant even after multiple prior lines.

She explains that selection among these therapies depends on disease pace, symptom burden, and prior tolerability rather than a fixed hierarchy. Everolimus and sunitinib are described as viable targeted approaches, particularly for patients seeking oral therapy and manageable toxicity profiles. Temozolomide based regimens are considered in selected cases, especially when greater tumor reduction is desired.

A key focus of this segment is the impact of prior PRRT on sequencing. Dr Shaheen notes that cumulative toxicity, including marrow reserve and long term tolerability, must be considered when layering additional therapies. She emphasizes careful monitoring and dose adjustments rather than exclusion of effective options.

This discussion highlights the longitudinal nature of pancreatic NET management. Dr Shaheen frames treatment as a continuum where past therapies inform but do not limit future choices. The goal remains sustained disease control while preserving patient function and minimizing cumulative burden, reinforcing the importance of thoughtful sequencing over time.